GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » PS Ratio

Kintor Pharmaceutical (HKSE:09939) PS Ratio : (As of Dec. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Kintor Pharmaceutical's share price is HK$1.05. Kintor Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00. Hence, Kintor Pharmaceutical's PS Ratio for today is .

The historical rank and industry rank for Kintor Pharmaceutical's PS Ratio or its related term are showing as below:

During the past 6 years, Kintor Pharmaceutical's highest PS Ratio was 39375.00. The lowest was 7.29. And the median was 98.81.

HKSE:09939's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.69
* Ranked among companies with meaningful PS Ratio only.

Kintor Pharmaceutical's Revenue per Sharefor the six months ended in Dec. 2023 was HK$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00.

During the past 6 years, Kintor Pharmaceutical's highest 3-Year average Revenue per Share Growth Rate was 289.30% per year. The lowest was 289.30% per year. And the median was 289.30% per year.

Back to Basics: PS Ratio


Kintor Pharmaceutical PS Ratio Historical Data

The historical data trend for Kintor Pharmaceutical's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical PS Ratio Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - 104.24 - -

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kintor Pharmaceutical's PS Ratio

For the Biotechnology subindustry, Kintor Pharmaceutical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintor Pharmaceutical's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's PS Ratio distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's PS Ratio falls into.



Kintor Pharmaceutical PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Kintor Pharmaceutical's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.05/0
=

Kintor Pharmaceutical's Share Price of today is HK$1.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Kintor Pharmaceutical  (HKSE:09939) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Kintor Pharmaceutical PS Ratio Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.
Executives
Tong Youzhi 2101 Beneficial owner
Kt International Investment Limited 2101 Beneficial owner
Guo Chuangxing 2201 Interest of corporation controlled by you
Kg Development Limited 2101 Beneficial owner
Nomura Holdings, Inc. 2201 Interest of corporation controlled by you
Tong Youzhi 2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si 2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si 2101 Beneficial owner

Kintor Pharmaceutical Headlines

No Headlines